Davita Inc. (DVA) Stock Price & Analysis
Davita Inc. (DVA) rose 3.18% to USD 198.19 as of June 9, 2026 at 23:44 UTC, according to Nexqual real-time market data.
DVA last closed at USD 192.08; the session ranged USD 193.69–198.25 on volume of 534,194 shares. Market capitalization is $12.72B, with a 52-week range of USD 101–202.69 (NYQ). Source: Nexqual, June 9, 2026 at 23:44 UTC.
Key Statistics (as of June 9, 2026 at 23:44 UTC)
| Price | USD 198.19 |
|---|---|
| Change | ▲ 3.18% (up) |
| Previous Close | USD 192.08 |
| Open | USD 193.63 |
| Day Range | USD 193.69 – 198.25 |
| 52-Week Range | USD 101 – 202.69 |
| Volume | 534,194 shares |
| Market Cap | $12.72B |
| Exchange | NYQ |
Technical Analysis (DVA)
Nexqual's technical model rates DVA "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 9, 2026 at 23:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 65.21 (neutral) |
| vs SMA50 | Above (USD 172.35) |
| MACD | 5.47 (positive) |
Analyst Ratings (DVA)
Wall Street analysts rate DVA "None" based on 7 analysts, with a mean price target of USD 193.71 (range USD 145–235), per Nexqual as of June 9, 2026 at 23:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 193.71 |
| High Target | USD 235 |
| Low Target | USD 145 |
| Buy / Hold / Sell | 2 / 4 / 2 |
Earnings (DVA)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 3.84 |
| Revenue Estimate | $3.49B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.87 vs est 2.33 ▲ beat |
| 2025-12-31 | USD 3.4 vs est 3.19 ▲ beat |
| 2025-09-30 | USD 2.51 vs est 3.17 ▼ miss |
| 2025-06-30 | USD 2.95 vs est 2.75 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Financials & Fundamentals (DVA)
| Total Revenue | $13.84B |
|---|---|
| Revenue Growth (YoY) | +6.00% |
| Gross Margin | +32.45% |
| Operating Margin | +13.86% |
| Profit Margin | +5.65% |
| ROE | +80.98% |
| Debt / Equity | 1,261.33 |
| Current Ratio | 1.42 |
| Total Cash | $666.55M |
| Total Debt | $13.22B |
| Free Cash Flow | $999.66M |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Financial Health Score (DVA)
Nexqual rates Davita Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:44 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 32%, operating 14% |
| Balance Sheet | Critical — $667M cash vs $13.2B debt |
| Cash Flow | Solid — FCF $1000M, 7% margin |
| Efficiency | Strong — ROE 81%, ROA 7.5% |
Ownership (DVA)
| Insider Ownership | +50.30% |
|---|---|
| Institutional Ownership | +52.56% |
| Shares Outstanding | 64.19M |
| Float | 34.09M |
| Short % of Float | +17.30% |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Leadership (DVA)
Davita Inc. is led by Javier J. Rodriguez (age 54), CEO & Executive Director, per Nexqual as of June 9, 2026 at 23:44 UTC.
| CEO & Executive Director | Javier J. Rodriguez (age 54) |
|---|---|
| CFO & Treasurer | Joel Ackerman (age 60) |
| Chief Operating Officer of DaVita Kidney Care | David P. Maughan (age 48) |
| Group Vice President of Investor Relations | Nic Eliason |
Major Backers & Investors (DVA)
Notable institutional backers of Davita Inc. include Berkshire Hathaway, Invesco, Morgan Stanley, according to Nexqual as of June 9, 2026 at 23:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Berkshire Hathaway | 46.89% |
| Invesco | 3.99% |
| Morgan Stanley | 2.6% |
| Arrowstreet Capital, Limited Partnership | 1.73% |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Quality Equity Fund | 0.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.64% |
| BlackRock | 4.98% |
| State Street | 2.72% |
| Dimensional Fund Advisors | 1.78% |
| Geode Capital | 1.46% |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
From Davita Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
- The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
- It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MCO | Moody's Corporation | USD 449.94 | ▼ 0.31% |
| UHS | Universal Health Services, Inc. | USD 146.59 | ▲ 0.98% |
| DGX | Quest Diagnostics Incorporated | USD 204.53 | ▲ 2.12% |
| LH | Labcorp Holdings Inc. | USD 271.24 | ▲ 2.3% |
| HCA | HCA Healthcare, Inc. | USD 374.9 | ▲ 0.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:44 UTC. This page is informational and not investment advice.